Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?

  • Ahead of Acadia Pharmaceuticals Inc's ACAD FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions.
  • The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has a target action date of August 4.
  • Initially, the FDA considered the Phase 2 trial, dubbed Study 019, insufficiently adequate and well-controlled, one of many reasons for the CRL, agency documents said. 
  • Related: Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis.
  • Study 019 involved patients whose psychotic symptoms were not clear or who received "exclusionary medications" when randomized into the study, the documents said. 
  • Acadia reconducted its primary endpoint analysis to measure the impact of these deviations, and the results came in favor of pimavanserin.
  • Also See: Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis.
  • "At this time, the Agency has determined that the study was designed with features that could allow it to be considered an adequate and well-controlled trial suitable for regulatory decision making," the documents read. 
  • "However, questions remain related to whether the methods of assessment of subjects' response are well defined and reliable."
  • Price Action: ACAD shares are up 12.8% at $18.33 during the market session on the last check Wednesday.

Posted In: Briefswhy it's movingBiotechNewsHealth CareFDAMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.